Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Specimen Handling 289Magnetic Resonance Spectroscopy 240pembrolizumab 223Carboplatin 183Biopsy 154Cyclophosphamide 148Cisplatin 145Paclitaxel 129Nivolumab 124Gemcitabine 114Bevacizumab 110Radiotherapy 87Dexamethasone 85Pemetrexed 81atezolizumab 78fludarabine 76Fluorouracil 75Doxorubicin 74Docetaxel 72Leucovorin 69Rituximab 68Radiation 68Oxaliplatin 66Prednisone 65venetoclax 64durvalumab 60Vincristine 59Cetuximab 56130-nm albumin-bound paclitaxel 56Immunoglobulin G 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × N-monoacetylcystine × 30 days × Clear all
NCT04481048 2026-06-05

DoDNAC

Children's Hospital Medical Center, Cincinnati

Phase 2 Completed
25 enrolled 12 charts
CNS

Attention Deficit Disorder with Hyperactivity, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡